Guggenheim Initiates Coverage on Eloxx Pharmaceuticals (NASDAQ:ELOX)

Equities research analysts at Guggenheim initiated coverage on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a report issued on Monday, Marketbeat reports. The brokerage set a “buy” rating and a $43.00 price target on the stock. Guggenheim’s price objective indicates a potential upside of 258.33% from the stock’s current price.

Eloxx Pharmaceuticals Stock Performance

Shares of NASDAQ ELOX opened at $12.00 on Monday. Eloxx Pharmaceuticals has a 12-month low of $11.26 and a 12-month high of $17.50. The firm has a market capitalization of $8.28 million, a P/E ratio of -0.78 and a beta of -1,891.27. The business’s 50 day simple moving average is $17.32.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.